During the past decade, Centro de Estudios de Investigacion Basica y Clinica SC. conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 9 clinical trials were completed, i.e. on average, 90% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 7 clinical trials were completed. i.e. 140% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centro de Estudios de Investigacion Basica y Clinica SC." #1 sponsor was "R-Pharm International, LLC" with 3 trials, followed by "Eli Lilly and Company" with 2 trials sponsored, "Galapagos NV" with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored and "Pfizer's Upjohn has merged with Mylan to form Viatris Inc." with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centro de Estudios de Investigacion Basica y Clinica SC." #1 collaborator was "OCT Clinical Trials" with 3 trials as a collaborator, "Quintiles, Inc." with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Amgen" with 1 trials as a collaborator and "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Centro de Estudios de Investigacion Basica y Clinica SC." are "Rheumatoid Arthritis" (9 trials), "Lupus Nephritis" (2 trials), "Active Systemic Lupus Erythematosus" (1 trials), "Arthritis, Rheumatoid" (1 trials) and "Chronic Low Back Pain With a Neuropathic Component" (1 trials). Many other conditions were trialed in "Centro de Estudios de Investigacion Basica y Clinica SC." in a lesser frequency.

Most popular intervention types in "Centro de Estudios de Investigacion Basica y Clinica SC." are "Drug" (16 trials), "Other" (3 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Adalimumab 40mg q2w" (1 trials), "Baricitinib" (1 trials), "Concomitant treatment" (1 trials) and "EU-Prolia" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centro de Estudios de Investigacion Basica y Clinica SC." are 16 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Centro de Estudios de Investigacion Basica y Clinica SC.". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Centro de Estudios de Investigacion Basica y Clinica SC., undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Centro de Estudios de Investigacion Basica y Clinica SC., 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".